Approaches to vaccination against Theileria parva and Theileria annulata by Nene, Vishvanath & Morrison, W Ivan
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Approaches to vaccination against Theileria parva and Theileria
annulata
Citation for published version:
Nene, V & Morrison, WI 2016, 'Approaches to vaccination against Theileria parva and Theileria annulata'
Parasite Immunology, vol. 38, no. 12, pp. 724-734. DOI: 10.1111/pim.12388
Digital Object Identifier (DOI):
10.1111/pim.12388
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Parasite Immunology
Publisher Rights Statement:
© 2016 The Authors. Parasite Immunology Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs
License, which permits use and distribution in any medium, provided the original work is properly cited, the use
is non-commercial and no modifications or adaptations are made.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
 wileyonlinelibrary.com/journal/pim Parasite Immunology 2016; 38: 724–734724  |  © 2016 The Authors. Parasite Immunology  
Published by John Wiley & Sons Ltd.
Received: 28 June 2016  |  Accepted: 15 August 2016
DOI: 10.1111/pim.12388
Summary
Despite having different cell tropism, the pathogenesis and immunobiology of the dis-
eases caused by Theileria parva and Theileria annulata are remarkably similar. Live vac-
cines have been available for both parasites for over 40 years, but although they provide 
strong protection, practical disadvantages have limited their widespread application. 
Efforts to develop alternative vaccines using defined parasite antigens have focused on 
the sporozoite and intracellular schizont stages of the parasites. Experimental vaccina-
tion studies using viral vectors expressing T. parva schizont antigens and T. parva and 
T. annulata sporozoite antigens incorporated in adjuvant have, in each case, demon-
strated protection against parasite challenge in a proportion of vaccinated animals. 
Current work is investigating alternative antigen delivery systems in an attempt to im-
prove the levels of protection. The genome architecture and protein- coding capacity of 
T. parva and T. annulata are remarkably similar. The major sporozoite surface antigen in 
both species and most of the schizont antigens are encoded by orthologous genes. The 
former have been shown to induce species cross- reactive neutralizing antibodies, and 
comparison of the schizont antigen orthologues has demonstrated that some of them 
display high levels of sequence conservation. Hence, advances in development of subu-
nit vaccines against one parasite species are likely to be readily applicable to the other.
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Approaches to vaccination against Theileria parva and  
Theileria annulata
V. Nene1 | W. I. Morrison2
1  | INTRODUCTION
Theileria are tickborne apicomplexan parasites found in tropical and 
subtropical regions of the world, where they predominantly infect ru-
minants.1–3 Wild and domestic ruminants harbour a large number of 
Theileria species, but only a few species, most notably Theileria parva 
and Theileria annulata in cattle and Theileria lestoquardi (previously also 
known as Theileria hirci) in sheep, are associated with severe clinical 
disease in farm animals.4–8 The diseases caused by these parasites 
are of major economic importance in the regions where they occur. 
Their geographical distribution is determined largely by that of the 
respective tick vector species. Theileria parva, which is transmitted 
predominantly by Rhipicephalus appendiculatus ticks, occurs in east-
ern and southern Africa, whereas T. annulata, transmitted by several 
species of Hyalomma ticks, occurs around the Mediterranean basin, 
north- east Africa, the Middle East, India and southern Asia. Theileria 
lestoquardi, which is closely related to T. annulata and is transmitted by 
the same tick species,9,10 appears to have a more restricted distribu-
tion, reports of infection being confined mainly to the Middle East and 
north- east Africa. Theileria parva and T. annulata also infect the African 
buffalo (Syncerus caffer) and the Asian buffalo (Bubalus bubalus), re-
spectively. The latter sometimes suffer mild clinical disease,11 whereas 
T. parva is nonpathogenic in the African buffalo, but infected buffalo 
represent an important wildlife reservoir for infection of cattle.12
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The pathogenic Theileria species cause acute lymphoproliferative 
diseases, with high levels of morbidity and mortality in susceptible 
populations of animals.6,13,14 Like malaria parasites, Theileria undergo 
sequential development in nucleated cells and erythrocytes, but 
pathogenicity is largely attributable to parasite development during 
the nucleated cell stage. Theileria invade leucocytes, but unlike most 
other apicomplexan parasites, they reside free within the cytosol of the 
host cells.15 Development to the schizont stage induces activation and 
proliferation of the infected host leucocytes,16 and, by associating with 
the mitotic spindle during cell division, the parasites are able to divide 
at the same time as the host cells, ensuring that infection is retained 
in the daughter cells.17–19 This process facilitates rapid parasite multi-
plication prior to differentiation to the erythrocyte- infective merozoite 
stage. In susceptible animals, large numbers of infected cells are found 
in the local lymph node draining the site of infection, from which they 
disseminate throughout the lymphoid system and to nonlymphoid 
tissues.20 Infection usually results in death within 3–4 weeks. The 
mode of replication of the schizont stage of T. parva, T. annulata and 
T. lestoquardi enables the parasitized cells of these species to be cul-
tured in vitro as continuously growing cell lines.21 These Theileria are 
frequently referred to as “transforming species”. Other species such as 
Theileria mutans and Theileria veliferi, which rarely cause disease, multi-
ply predominantly during the intra- erythrocytic stage of development 
and undergo limited replication in nucleated cells (reviewed in Ref. 22).
The intra- erythrocyte piroplasm stage of T. parva undergoes little 
or no multiplication, whereas there is some replication of T. annu-
lata piroplasms,23 which is associated with higher levels of infection 
of erythrocytes. Infections with T. annulata may result in moderate 
anaemia and occasionally jaundice, although pathology produced by 
the schizont stage is usually the primary cause of mortality by both 
species.
Because of the acute and fatal nature of the Theileria infections in 
susceptible stock, control of the diseases is particularly challenging. 
In the past, prevention of tick infestation by application of acaricides 
has been used successfully to prevent disease. However, the need for 
almost continuous use of these chemicals has proved to be expensive 
and difficult to sustain and runs the risk of selecting acaricide- resistant 
tick populations. A single therapeutic compound (buparvaquone, mar-
keted as Buparvex) is available,24 but its use is limited by cost and the 
need to treat animals during the early stages of disease to be effective. 
Moreover, there are recent reports of the emergence of drug- resistant 
strains of T. annulata.25,26
Due to the shortcomings of these control measures, it has long 
been recognized that vaccination is the most sustainable option for 
control of these diseases. Live vaccines were produced for T. parva 
and T. annulata over 40 years ago,5,27,28 but have a number of practical 
disadvantages that have limited their use in many areas. Efforts to de-
velop vaccines based on use of defined antigens have so far met with 
limited success. These recent studies have been the subject of several 
recent reviews.29–31 Herein, we will discuss the current status of vacci-
nation against T. parva and T. annulata and consider the potential value 
of comparative studies of these parasites for future development of 
improved vaccines.
2  | THEILERIA PARVA  AND THEILERIA 
ANNULATA  INFECT DIFFERENT CELL TYPES 
BUT CAUSE SIMILAR IMMUNOPATHOLOGY
The ability to infect bovine cells in vitro with tick- derived sporozoites 
has enabled the cell tropism of the different Theileria species to be 
determined. Early studies demonstrated that T. parva sporozoites can 
bind to and infect B and all subsets of T lymphocytes in vitro with 
similar efficiency, whereas T. annulata was found to infect monocytes 
and B lymphocytes but not T lymphocytes.32,33 Subsequent analyses 
of the cells infected by T. parva in vivo showed that the vast majority 
of the infected cells in animals undergoing primary infection were T 
cells, of both CD4 and CD8 T- cell lineage.34 Moreover, experiments 
in which purified cell populations were infected in vitro with sporozo-
ites and then administered to the autologous animals after 24 hours 
(when no viable sporozoites remained) demonstrated that infected T 
cells produced lethal infections, whereas infected B cells resulted in 
transient mild infection from which they recovered.35 In the animals 
that received T. parva- infected B cells, infection was first detected in 
the regional lymph node around the same time as in animals receiv-
ing infected T cells, but they were able to clear the infection around 
11–12 days after infection and were subsequently immune to parasite 
challenge. We have recently shown that animals inoculated with in-
fected autologous T cells that have been cultured in vitro for 6 weeks 
or more also develop similar mild self- limiting infections (Morrison WI 
and Connelley T, unpublished data). Based on these findings, we have 
concluded that transformation of the infected cells alone is not suf-
ficient for virulence and that additional as yet undefined properties 
of recently infected T cells enable them to produce disease. Recent 
studies have identified a Zambian isolate of T. parva that infects CD8 
T cells but not CD4 or γ/δ T cells.36 Infection with this isolate results 
in disease, although the authors suggested that it is of lower viru-
lence than other isolates. The relative contribution of infected mono-
cytes and B cells to infections with T. annulata in vivo has not been 
determined.
Despite the different cell tropisms of T. parva and T. annulata, the 
pathology they produce is remarkably similar. In both infections, the 
parasitized cells migrate from the site of infection and become dis-
seminated throughout the lymphoid system. In both cases, there is 
also evidence of an early powerful nonspecific T- cell response in an-
imals experimentally infected with a lethal dose of sporozoites, but 
this response appears to be ineffective in controlling the infection. In 
the case of T. parva, the regional lymph node was found to contain 
15%–20% lymphoblasts at a time when there was <1% parasitized 
cells.37 A majority of these cells were CD8 T cells, including a pheno-
typically unusual subset of CD2−CD8+ cells; they did not show any 
cytotoxic activity against parasitized cells and also failed to respond 
to antigenic or mitogenic stimulation in vitro. Separate studies of an-
imals infected with T. annulata revealed a broadly similar picture.38–40 
These observations have not been investigated further, nor has there 
been any comparison of the responses to infections induced by needle 
and tick challenge. Nevertheless, currently available data indicate that 
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the progressive nature of infections with the two parasite species is 
not due to a failure to stimulate an immune response but rather that 
the infection stimulates a dysregulated immune response that fails to 
differentiate to generate appropriate effector functions. This presum-
ably reflects a strategy by the parasites to delay parasite clearance. 
What is remarkable is that infection of different cell types by the two 
Theileria species results in a very similar outcome. Further research 
using contemporary methodologies is required to understand the 
molecular basis of these immune responses, to better inform what is 
required for appropriate differentiation of a protective vs a nonprotec-
tive immune response.
3  | LIVE VACCINES
3.1 | Vaccination with parasitized cell lines
The advent in the 1960s of cell culture systems to propagate Theileria- 
infected cells as continuously growing cell lines in vitro opened up an 
obvious opportunity to investigate the use of these cells for vaccina-
tion. However, the results obtained with T. annulata and T. parva were 
very different. Administration of 105 or fewer T. annulata- infected 
cells resulted in immunity to parasite challenge, although prolonged 
in vitro passage of the cell lines was required to avoid production of 
clinical disease by the vaccine.5,27,41 Initial studies in Israel in the early 
1970s resulted in a national vaccine programme for T. annulata using 
cultured cells. Similar vaccines were subsequently developed in sev-
eral other countries using cell lines derived from local parasite isolates. 
These vaccines are generally produced in batches that are cryopre-
served in aliquots in liquid nitrogen and thawed immediately before 
use. A dose of approximately 1–5 × 106 cells (equivalent to 1–5 mL of 
cultured cells) is used, which allows considerable leeway for cell loss 
during freezing and thawing of the vaccine.5
By contrast to T. annulata, similar studies with T. parva demon-
strated that a dose of 108 cultured cells was required to generate im-
munity in all animals.42 Similar to T. annulata, in vitro passage of the 
cells (>50 passages) was required to avoid production of disease by 
the inoculated cells. As 108 cells represented >100 mL of culture, this 
method of vaccination was not considered economically viable.
Subsequent studies demonstrated that, for both parasite spe-
cies, transfer of the parasites from the donor culture cells into cells 
of the recipient animals is required for successful induction of im-
munity and that this transfer occurs at much lower frequency with 
T. parva than with T. annulata.43,44 This reflects a requirement of 
protective T- cell responses to recognize parasite antigens in the 
context of the major histocompatibility complex (MHC) of the re-
cipient animal. Analyses of immune responses in vaccinated ani-
mals demonstrated that animals generated a CD8 T- cell response 
directed against alloantigens on the inoculated cells at 7–10 days, 
followed by a second CD8 T- cell response about a week later, which 
was parasite specific and restricted by the MHC of the recipient an-
imal. The mechanisms by which the schizonts transfer from one cell 
to another are not known, nor is it clear why this occurs with greater 
efficiency in T. annulata.
3.2 | Vaccination by infection with sporozoites
The unfeasibility of using cultured parasites for vaccination against 
T. parva prompted alternative methods of immunization with live 
parasites. With the development of methods to cryopreserve large 
stocks of sporozoites, in the form of homogenized infected ticks,45 
titrations of this material in cattle were undertaken with the aim of 
identifying a dose that would reproducibly result in mild transient 
infections and immunity. However, this was not achievable because 
the lowest doses that produced infection in all animals still resulted 
in severe reactions in some of the animals.46 An alternative approach 
involving infection and simultaneous treatment with oxytetracycline 
was developed, which successfully achieved mild transient infections 
in all animals.28,47 Use of a long- acting formulation of oxytetracycline 
that provided 5–6 days of activity was required to control the infec-
tion. This so- called infection and treatment immunization procedure 
resulted in long- lasting immunity in all animals against high challenge 
doses of the T. parva isolate used for immunization, but only a pro-
portion of immunized animals withstood challenge with other para-
site isolates.48,49 However, based on a series of experiments involving 
immunization and challenge of cattle with different combinations of 
parasite isolates, a mixture of three isolates was identified (known as 
the Muguga cocktail), which when used to immunize cattle gave broad 
protection against experimental challenge with different parasite iso-
lates and against field challenge with T. parva. Despite evidence of ef-
ficacy,50 until recently use of the Muguga cocktail vaccine in the field 
has been limited.
3.3 | Shortcomings of live Theileria vaccines
3.3.1 | Practical constraints
Vaccination using the Muguga cocktail requires production of three 
large batches of T. parva sporozoites by feeding ticks on cattle in-
fected with each parasite isolate, and each batch needs to be carefully 
titrated in cattle to determine a dose that will reproducibly infect and 
immunize all animals but will not break through the tetracycline treat-
ment. This complex protocol coupled with the requirement for a liquid 
nitrogen cold chain to distribute the vaccine presents challenges for 
quality control and marketing. However, recent initiatives have led to 
increased field uptake. This has included the establishment of a cen-
tre for vaccine production and systems to facilitate distribution of the 
vaccine.
3.3.2 | Parasite strain- restricted immunity
As referred to above, vaccination against T. parva by infection and 
treatment was found to require incorporation of three parasite iso-
lates in the vaccine to provide immunity against field challenge. This 
followed on from field studies in which animals immunized with a sin-
gle parasite isolate were not protected, providing the first convinc-
ing evidence of antigenic heterogeneity in T. parva.51 More extensive 
testing of the Muguga cocktail vaccine has demonstrated that it does 
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not provide complete protection against field challenge in all circum-
stances, in particular against challenge with buffalo- derived para-
sites.52,53 Indeed in one study, vaccinated animals introduced into an 
area grazed only by buffalo showed no protection.52 These findings 
are consistent with sequencing data on parasite genes encoding two 
polymorphic antigens (Tp1 and Tp2) and genomewide SNP density, 
which revealed much greater genotypic diversity in parasites isolated 
from buffalo compared with those of cattle origin.54
The results of two recent studies of the Muguga cocktail vaccine, 
one involving genomic sequencing of the three component parasites55 
and the other based on high- throughput sequencing of PCR ampli-
cons of six genes encoding T. parva antigens (including Tp1 and Tp2),56 
have indicated that the vaccine contains only a small component of 
the genetic and antigenic diversity detected in field populations of 
T. parva. Each of the three parasite isolates in the Muguga cocktail ex-
hibited very limited diversity, and two of them (Muguga and Serengeti) 
showed a remarkably high level of sequence similarity, but differed 
significantly from the third isolate (Kiambu). The Serengeti parasite 
was originally isolated from a buffalo and adapted to tick transmission 
between cattle following several tick passages. However, the results 
of these two studies both suggested that the Serengeti isolate had at 
some point become contaminated with parasites from the Muguga iso-
late. Amplicon sequencing and satellite DNA typing also demonstrated 
that the vaccine components contained minor genotypic components 
present at <5% within the vaccine parasites.56 If these minor com-
ponents contribute to the broad protective capacity of the vaccine, 
then the possibility that these components might not be present in 
all vaccine batches or indeed all vaccine doses is of concern regarding 
standardization of vaccine content. The authors proposed formulating 
an alternative vaccine comprising a mixture of antigenically divergent 
parasite clones, to standardize the content of the vaccine and poten-
tially enhance its ability to generate broadly cross- reactive immunity. 
This material would have to be derived through tick passage, and the 
influence on parasite homogeneity through sexual recombination 
would need to be investigated.
It is of note that antigenic heterogeneity among isolates of T. an-
nulata has also been documented in a number of early studies, which 
showed incomplete cross- protection between some isolates, with a 
proportion of the animals succumbing to disease (reviewed in Ref. 4,5). 
Moreover, initial cell line vaccine testing in Israel showed that vacci-
nated animals challenged with heterologous parasite isolates devel-
oped more severe clinical reactions than those receiving homologous 
challenge, although the animals survived. More recently, experiments 
involving immunization of cattle with cell lines infected with Tunisian 
T. annulata isolates have indicated that the passage history of the cell 
line can influence the level of protection against heterologous iso-
lates57; cattle immunized with cell lines that had undergone prolonged 
passage suffered more severe reactions following challenge than 
those immunized with the same cell lines at an earlier level of passage. 
Analyses of these cell lines with isoenzymes and polymorphic geno-
typic markers indicated that prolonged passage resulted in reduced 
genetic diversity in the parasites within the cell lines, and these au-
thors suggested that this loss in diversity may account for the reduced 
capacity to provide protection against challenge with heterologous 
parasite isolates. Nevertheless, the reasons why strain- restricted im-
munity, as observed with T. parva, is not a major issue when vaccinat-
ing cattle against T. annulata are unclear.
3.3.3 | Acceptability of live vaccines
A key feature of infections with Theileria parasites is their ability to 
establish persistent infections in the face of immune responses that 
control the infection. In the case of T. parva and T. annulata, persis-
tent infections (referred to as the carrier state) are usually not de-
tectable microscopically but can be revealed by polymerase chain 
reaction (PCR) assays and can be transmitted by ticks.58 The live para-
sites used for vaccination often retain the ability to establish a carrier 
state, although some of the T. annulata cell line vaccines that have 
been subjected to prolonged in vitro passage are claimed to have lost 
this property. Nevertheless, there has been great reluctance to use 
live parasites originating in one country to vaccinate animals in other 
countries, because of perceived risks of introducing “foreign parasite 
strains” of different antigenic composition or virulence. Hence, for 
T. annulata, each country has tended to develop its own cell line vac-
cine from a local parasite isolate. In the case of T. parva, use of the 
Muguga cocktail vaccine has been slow to gain acceptance outside 
Kenya and Tanzania. In the longer term, this issue could potentially be 
addressed by genetically modifying the parasite such that the carrier 
status is no longer maintained.
4  | APPROACHES TO DEVELOPMENT OF 
SUBUNIT VACCINES
Because of the limitations of available live vaccines, efforts have been 
made to develop alternative vaccines based on the use of defined an-
tigens. This has necessitated studies to understand the immune re-
sponses to the parasites and their role in immune protection. Much of 
this work has focused on the sporozoite and schizont developmental 
stages.
4.1 | Protective immune responses to schizont- 
infected cells
4.1.1 | Immune protection
There is a large body of evidence indicating that immunity generated 
by infection with T. parva or T. annulata is mediated by cellular im-
mune responses directed against schizont- infected leucocytes. This 
information has been reviewed elsewhere29,30 and will therefore only 
be summarized briefly here.
Because animals can be immunized by administration of schizont- 
infected cell lines, immunity is clearly not dependent on exposure to 
preschizont stages of the parasite. Moreover, immunization with live 
parasites, either cell lines or sporozoites, does not prevent establish-
ment of infection, but rather schizont- infected cells are often detected 
728  |     NENE aNd MORRISON
transiently 8–10 days after parasite challenge of immunized animals, 
indicating that immunity operates against this stage of the parasite.
Analyses of the immune responses ex vivo following challenge 
of T. parva- immunized animals have demonstrated MHC- restricted 
cytotoxic CD8 T- cell responses against autologous T. parva- infected 
cells, coinciding with parasite clearance.59,60 Two further observations 
provided evidence that these T cells are key mediators of immunity 
to T. parva. First, transfer of responding CD8 T cells (but not CD4 T 
cells), from immune to naïve identical twin calves, was found to confer 
protection against parasite challenge in the naïve recipients.61 Second, 
the CD8 T- cell responses showed parasite strain specificity that varied 
between animals immunized with the same parasite isolate, and cor-
related closely with the observed immunity following challenge with a 
cloned heterologous parasite strain.62,63 Further studies have demon-
strated high frequencies of parasite- specific CD8 T- cell precursors in 
the memory T- cell populations of immune animals,63 and the specific-
ities of these T cells have been studied in detail using CD8 T- cell lines 
and clones derived from the memory populations.64,65 Analyses of 
T- cell lines obtained from immune animals by stimulation with autolo-
gous parasitized cells have also identified strong parasite- specific CD4 
T- cell responses, which recognize antigen presented on the surface of 
infected leucocytes.66,67 Findings from in vitro experiments involving 
mixing of CD4 and CD8 T cells from immune or naïve animals have 
indicated that the parasite- specific CD4 T cells may provide help for 
induction and recall of parasite- specific CD8 T- cell responses.68
While the role of T- cell responses in immunity to T. annulata has 
not been examined in the same detail, available evidence indicates 
a very similar profile of responses, namely cytotoxic CD8 T- cell re-
sponses detected ex vivo following immunization and challenge with 
the parasite and the presence of CD4 and CD8 T cells specific for 
autologous parasitized cells in T- cell lines generated in vitro from im-
mune animals.69,70
4.1.2 | The antigens recognized on schizont- 
infected cells
A series of studies using T. parva- specific CD8 T- cell lines to screen for 
recognition of cells transfected with parasite cDNAs has identified 10 
antigens (Table 1) that are recognized by CD8 T cells from immune cat-
tle.56,71 The genes encoding these antigens are unrelated and are distrib-
uted across the genome. Some are predicted to be orthologues of other 
parasite and/or mammalian genes, whereas others have no detectable 
orthologues. A striking feature of the antigen screening results was that 
animals of different MHC genotypes tended to detect different T. parva 
antigens, and, within the animals studied, only one of the antigens (Tp2) 
was recognized by T cells from animals of several different MHC geno-
types. Epitope screening, in most cases, also identified a single domi-
nant epitope recognized by T cells restricted by a given MHC allele.72 
However, animals of some MHC types do not recognize any of these 
antigens. The results of these studies collectively indicate that a large 
number of T. parva proteins are capable of eliciting CD8 T- cell responses 
and that many of these target antigens have not yet been identified.
Detailed analyses of the responses to two of the antigens, Tp1 and 
Tp2, which are recognized on the A18 and A10 MHCI backgrounds, 
TABLE  1 Level of amino acid sequence conservation between orthologues of schizont vaccine antigens in Theileria parva and Theileria 
annulata
Theileria parva Theileria annulata
Ta/Tp amino acid identitycAntigen Amino acids Epitope sequence Antigena Amino acids Epitope sequenceb
Tp1 543 214VGYPKVKEEML224 Ta1 529
214YKYPNIKQEML224 52%
Tp2 175 27SHEELKKLGML37 Ta2 178
28KDEELDAMGML38 60%
40DGFDRDALF48
41DLNKELLFQ49
49KSSHGMGKVGK59
50QTSHILTKVGK60
96FAQSLVCVL104
97FAASIHCVA105
98QSLVCVLMK106
99ASIHCVANK107
138KTSIPNPCKW147
139KESIPNPCDW148
Tp3 265 Unknown Ta3 265 77%
Tp4 579 328TGASIQTTL336 Ta4 520
328TGASIQTTL336 96%
Tp5 155 87SKADVIAKY95 Ta5 155
87SKADVIAKY95 98.1%
Tp6 277 Unknown Ta6 277 98.5%
Tp7 721 206EFISFPISL214 Ta7 722
206EFISFPISL214 97.5%
Tp8 434 373CGAELNHFL381 Ta8 409
352CGAELNHYL360 89%
Tp9 335 67AKFPGMKKS75 Ta9 336
64SKFPKMRMG72 64%
Tp10 443 419NNPELIPVL427 Ta10 447
423NNPELIPVL431 92%
aOnly Ta5 and Ta9 (bold) confirmed as CD8 T- cell antigens in T. annulata.
bDivergent amino acid residues are highlighted in grey.
cThe percentage of amino acid residues conserved between the T. parva and T. annulata orthologues, based on the reference genome sequences.
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respectively, demonstrated that in each case, approximately 70% of 
the parasite- specific CD8 T cells in MHC- homozygous immune ani-
mals were specific for the respective antigen and that these animals 
did not recognize the other defined antigens.65 Subsequent work 
demonstrated that these antigens are highly polymorphic and that 
the respective T- cell responses are often parasite strain- restricted. 
Elsewhere, we have discussed in further detail how this observed fo-
cusing of the CD8 T- cell response on highly dominant polymorphic 
T- cell epitopes is a key determinant of parasite strain specificity of 
CD8 T- cell response.65,73 However, recent unpublished studies (H. 
Hemmink, W.I. Morrison, P. Toye, T. Sitt and W. Weir, manuscript in 
preparation) have shown that several of the other T. parva CD8 T- cell 
antigens are highly conserved among field isolates of the parasite.
Similar large- scale antigen screening has not been undertaken with 
T cells specific for the other pathogenic Theileria species. However, 
screening for recognition of the orthologues of the 10 T. parva anti-
gens in T. annulata74 and T. lestoquardi75 has been conducted with a 
limited number of CD8 T- cell lines from cattle and sheep, respectively. 
In each case, positive results were obtained with two antigens (Tp5 
and Tp9 orthologues in T. annulata and Tp8 and Tp9 orthologues in 
T. lestoquardi). An additional T. annulata antigen was identified by 
screening a small number of parasite cDNAs. Analyses of sequences of 
Tp9 and the orthologue in T. annulata in different parasite isolates have 
shown that this antigen is highly polymorphic in both parasite species 
56,74 and that the corresponding CD8 T- cell lines exhibit parasite strain 
specificity. Although the repertoire of antigens recognized by CD8 T 
cells specific for these parasites is far from complete, these initial find-
ings suggest that there is likely to be substantial commonality in the 
gene products that they recognize. Hence, information from one spe-
cies can help to focus efforts on antigen screening in the other species.
4.1.3 | Vaccination with schizont antigens
Five of the T. parva antigens recognized by CD8 T cells, including Tp1 
and Tp2, have also been tested for their ability to induce immune 
responses and protection against parasite challenge.71 These experi-
ments involved the use of prime–boost protocols involving priming 
with plasmid DNA or recombinant canarypox viruses followed by a 
single boost with replication- defective recombinant vaccinia viruses 
(Ankara strain). Animals were immunized simultaneously with five of 
the antigens in separate DNA or viral constructs. Most of the immu-
nized animals (19 of 24) exhibited readily detectable antigen- specific 
CD8+ T- cell IFN- γ responses following immunization, but the CD8 T 
cells only exhibited detectable cytotoxic activity for parasitized cells 
in four of the 24 immunized animals.71
The animals were challenged along with unimmunized controls 
with a lethal dose of sporozoites 3 weeks after the booster immuni-
zation. Nine of the 19 immunized animals that generated a specific 
CD8 T- cell IFN- γ response, including the four whose CD8 T cells ex-
hibited cytotoxicity, survived the challenge, although some of them 
developed moderate- to- severe clinical reactions prior to recovery. 
There was a significant association between survival and the induction 
of a cytotoxic CD8 T- cell response. Thus, although the immunization 
protocols used in this study clearly did not induce a level of immunity 
that is of practical value for vaccination, they resulted in reduction in 
severity of disease and survival in a proportion of the animals.
Subsequent experiments in which similarly immunized cattle were 
treated with DNA- encoded FLT3L and GM- CSF, in an attempt to in-
crease targeting of the expressed antigen to dendritic cells, failed to 
enhance protection.76
The results obtained from these initial vaccination experiments in-
dicated that the vaccine- induced CD8 T- cell responses to schizont an-
tigens may not be fully functionally competent to provide protection 
against parasite challenge. Current studies are investigating differ-
ences in the function of the specific CD8 T cells induced by live para-
sites and the subunit proteins and exploring the utility of alternative 
antigen delivery systems, including improved replication- defective 
poxvirus vectors and other alternative viral vectors. The potential con-
tribution of other cell subsets, such as CD4 T cells, to protection is also 
being investigated.
4.2 | Protective immune responses to sporozoites
Although infections with T. parva77 or T. annulata78 induce only low 
levels of antibody against sporozoite antigens, antibodies capable 
of fully neutralizing the infectivity of sporozoites in vitro have been 
detected in animals subjected to repeated sporozoite challenge. 
Moreover, monoclonal antibodies with neutralizing activity (nmAbs) 
have been produced for both parasites by immunizing mice with 
sporozoites.79–81 The majority of such antibodies recognize a sporo-
zoite surface protein, called p67 in T. parva82 and SPAG1 in T. annu-
lata.81 Allelic variants of the SPAG1 protein are detected in parasites 
derived from both cattle and Asian buffalo.83 While allelic variants of 
p67 have been detected, they appear to be found primarily in para-
sites derived from the African buffalo rather than from cattle- derived 
parasites.84,85
The p6786 and SPAG181 proteins are encoded by single copy genes 
and consist of ~700 and ~900 amino acid residues, respectively. They 
are major components of the sporozoite surface membrane. Like the 
circumsporozoite protein (CSP) of Plasmodium sporozoites,87 the p67/
SPAG1 proteins play a role in host cell recognition and entry, but 
they are not expressed in the schizont stage. Recombinant p6788 and 
SPAG189,90 incorporated in adjuvant induce sporozoite neutralizing 
activity in cattle and induce immunity to sporozoite needle challenge 
in a proportion of immunized cattle. In most of these experiments, the 
sporozoite challenge dose was titrated to provide less than an LD100.
A large number of cattle laboratory challenge experiments have 
been carried out with various different forms of recombinant p67 with 
different adjuvants and vectored antigen delivery systems, which has 
been recently reviewed.31 In brief, recombinant protein gave superior 
results to the vectored systems used and immunity to severe ECF 
ranged from 20% to ~70%. A range of different clinical responses to 
challenge was observed, from no- reaction to mild, moderate and se-
vere disease. It is likely that in the first of these categories of animals, 
no infection occurred, as these cattle were negative by PCR. Immunity 
induced by SPAG1 and different forms of SPAG1 has been less well 
730  |     NENE aNd MORRISON
studied, but as with p67 has been found to induce significant levels of 
immunity (~50%) to challenge.90 Interestingly, the SPAG1 protein has 
been shown to synergize with the protective efficacy of the Tams- 1 
protein91,92 and a live attenuated T. annulata cell line,93 indicating that 
there is merit in assessing the role of multiple parasite antigens in in-
creasing the efficacy of candidate vaccine antigens.
Expression of recombinant p67 in a native and stable form remains 
a technical challenge. Mapping of linear B- cell epitopes on p67 has re-
vealed that the bovine immune response to recombinant full- length p67 
is primarily directed to N- and C- terminal domains, which also harbour 
linear epitopes recognized by nmAbs.94 This has led to the demonstra-
tion that an easy- to- produce 80 amino acid peptide at the C- terminal 
end of p67, called p67C, induces the same level of immunity to full- 
length p67.95 This immunogen is now being used to further optimize 
protective immune responses to ECF. A 108 amino acid C- terminal pep-
tide of SPAG1 fused to hepatitis B core antigen has also been shown to 
induce immunity equivalent to that of full- length SPAG1.89
The polymorphic immunodominant molecule (PIM) in T. parva is 
also a target of murine nmAbs,96,97 but as cattle do not make neutral-
izing antibodies to full- length recombinant PIM, this antigen has not 
been tested in challenge experiments.98,99 PIM is expressed in both 
sporozoites and schizonts. An orthologue of this protein, called TaSp 
100 and TlSP,101 is present in T. annulata and T. lestoquardi. The PIM 
antigen is rich in glutamine and proline amino acid residues and con-
sists of a complex central domain that is variable in length flanked by 
conserved N- and C- terminal sequences.98 Sequence variation in the 
central domain results in the PIM antigen ranging in size from 62 to 
112 kDa. In contrast, the TaSP antigen does not exhibit the extreme 
size polymorphism of PIM and is about 36 kDa in size.100 Although 
allelic variants are found, the TaSP variants do not contain the complex 
central domain observed in the PIM antigen. As its name implies, cattle 
mount a strong antibody response to PIM and this antigen is used as 
a serological diagnostic test as a marker of T. parva infection.102 The 
TaSP protein has also been used to develop a serological diagnostic 
test as a marker of T. annulata infection.103
5  | COMPARATIVE THEILERIA PARVA  AND 
THEILERIA ANNULATA  GENOMICS
Available information on the antigens recognized by protective im-
mune responses in the two Theileria species indicates that the immune 
responses are directed to the products of orthologous genes and in 
some instances have provided evidence of antigenic cross- reactivity. 
Herein, we will explore this further to consider whether there is scope 
for inducing protective responses that are active against both parasite 
species.
5.1 | Conservation in genome architecture and 
gene content
The genome architecture and protein- coding capacity of T. parva and 
T. annulata are remarkably similar. Theileria parva104 and T. annulata105 
each encode four Mbp- sized nuclear chromosomes, a small linear mi-
tochondrial (~7 kbp) 106,107 and circular apicoplast (~ 39 kbp) genome 
with a total genome size of ~8.35 Mbp. Gene density is very high in 
both organisms, with T. parva predicted to code for a larger number 
of chromosomal encoded proteins (4035) than T. annulata (3792). It 
should be highlighted that these data were generated over a decade 
ago and there has been much improvement in bioinformatics and 
sequencing tools in the interim. The reference T. parva genome has 
been resequenced and re- annotated and gene models were refined 
using RNAseq data from the schizont stage (cited in108), which has 
resulted in substantial change in exon–intron boundaries and in the 
discovery of additional protein- coding genes. A similar exercise is 
being undertaken for T. annulata (A. Pain, personal communication). 
Comparative data on the physical map of chromosomes suggest that 
the total size of the T. parva genome can vary between different para-
site isolates.109 The impact of genome size variations on parasite gene 
content and biology, however, remains to be fully documented. Such 
data are beginning to accumulate for T. parva as more strains are se-
quenced55,110,111 and their impact on genotypic diversity has been 
briefly reviewed elsewhere.31
Both genomes exhibit a highly compact structure. In brief, chromo-
somal DNA does not contain highly repetitive DNA, and telomeres are 
short, and noncoding subtelomeric sequences in T. parva are simpler 
in sequence than those found in T. annulata.105 A high proportion of 
protein- coding genes encode introns that tend to be short, and in-
tergenic regions are also short. The T. parva and T. annulata genomes 
exhibit near complete synteny across all four chromosomes, with in-
terruptions due to insertions or deletions of members of the multigene 
families.105,112 The most notable inversion point relates to the T. parva 
Tpr locus, which occupies a region of ~150 kbp within chromosome 3 
and consists of a large tandem array of open reading frames. Members 
of the equivalent gene family in T. annulata, Tar, are dispersed across 
the nuclear genome. There are no interchromosomal rearrangements.
5.2 | Conservation of candidate Theileria parva and 
Theileria annulata vaccine antigens
5.2.1 | Sporozoite antigens
Although the p67 and SPAG1 proteins exhibit only 47% sequence 
identity, there is sufficient conservation of epitopes between them so 
that anti- p67 serum recognizes SPAG1 in immunoblots and neutralizes 
in vitro the infectivity of T. annulata sporozoites, and vice versa.113 This 
functionality even extends to some nmAbs. mAb 23F raised to p67 in-
hibits T. annulata sporozoite infectivity, and mAb 1A7 raised to SPAG1 
inhibits T. parva sporozoite infectivity. By Pepscan analysis on p67, 
1A7 has been shown to bind to the core peptide sequence PSLVITD. 
The sequence PSLVI is present in SPAG1.113 mAb 23F binds a con-
formational epitope in p67, which remains to be mapped. An ortho-
logue of p67/SPAG1 is also present in T. lestoquardi, called SLAG1.114 
Encoding 723 amino acid residues, the protein shares 42% and 58% 
sequence identity with p67 and SPAG1, respectively. The higher 
level of sequence identity with SPAG1 is perhaps not unexpected as 
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T. lestoquardi is a closer relative to T. annulata than T. parva (reviewed 
in Ref. 115) Abs to a fragment of SLAG1 bind to p67 and SPAG1 and 
SLAG1 also contains the sequence PSLVI, which predicts that 1A7 
should bind and inhibit T. lestoquardi sporozoites and that these three 
molecules are antigenically related.115 The ability of p67 and SPAG1 
to induce cross- species immunity has been confirmed,116 namely that 
p67 immunized cattle can exhibit immunity to T. annulata sporozoite 
challenge and vice versa. Both antigens induced approximately 50% im-
munity to the homologous and heterologous sporozoite challenge. The 
role of SLAG1 as a candidate vaccine antigen remains to be tested, but 
given that p67 also protects a proportion of cattle against ECF under 
field conditions, that is, through parasite tick challenge,117 this group of 
related proteins are prime candidate vaccine antigens.
5.2.2 | Schizont antigens
As discussed above, CD8 T- cell responses specific for T. annulata have 
been shown to recognize orthologues of two of the T. parva CD8 T- cell 
target antigens identified to date. Moreover, the amino acid sequence 
of the epitope identified in one of these antigens (Ta5) 74 was identical 
to that in the Tp5 protein,72 although it was presented by a different, 
but related MHC class I allele (1*00902 presented Tp5 and 1*02301 
presented Ta5). Comparison of the predicted amino acid sequences of 
the 10 identified T. parva CD8 antigens with their T. annulata ortho-
logues, based on the respective reference genome sequences, reveals 
a high level of sequence conservation between the orthologues of a 
number of the antigens (Table 1). Thus, Tp4, Tp5, Tp6 and Tp7 ex-
hibit >96% sequence identity and Tp8 and Tp10 between 89% and 
92% identity with their T. annulata counterparts. Remarkably, the se-
quences of the CD8 T- cell epitopes identified in four of these antigens 
are also completely conserved between the species. The lower levels 
of identity observed for Tp1, Tp2 and Tp9 are consistent with previ-
ous evidence that these antigens are highly polymorphic in T. parva 
and, in the case of Tp9, also T. annulata.
The question of whether or not there is any cross- protection be-
tween these Theileria species has not been addressed in any recent 
studies although a review by Neitz in 19574 reported that animals 
recovered from infection with T. annulata remained susceptible to 
T. parva. However, in T. parva, CD8 T- cell responses are often domi-
nated by T cells specific for more polymorphic antigens30; hence, any 
cross- immunity might only be partial and/or only apparent in a subset 
of animals. Evolutionary divergence of pathogen species within the 
same host is usually associated with antigenic divergence to minimize 
interspecies competition. However, as the geographical distributions 
of T. parva and T. annulata do not overlap, due to the different distri-
bution of their tick vectors, there may have been minimal selective 
pressure to maintain antigenic divergence between these species. 
In the absence of a proven antigen delivery system for induction of 
protective CD8 T- cell responses with defined antigens, it is currently 
not possible to determine the protective potential of these conserved 
antigens. In the meantime, further studies to examine potential cross- 
protection between the two species, linked to analyses of the speci-
ficity of the T- cell responses, may help to shed light on this question.
6  | CONCLUSIONS
As described above, there is a great deal of similarity in the im-
munopathology, genomics and biology of T. parva and T. annu-
lata. Similar protective immune responses are directed against the 
sporozoite and schizont stages of the parasites, and it is remarkable 
that many candidate sporozoite and schizont antigens are also so 
similar to each other. Hence, advances in development of subunit 
vaccines against one parasite species are likely to be readily appli-
cable to the other. The data on antigenic conservation between the 
two species are contrary to expectation, as early research reported 
that cattle immunized with live parasites exhibited species- specific 
immunity4, suggesting that unique antigens were likely to play a 
role in immunity to infection. However, what we now know about 
the nature of the immune response to T. parva and T. annulata may 
offer an explanation for the apparent lack of cross- protection. First, 
the sporozoite antigens are not highly immunogenic molecules per 
se. Although there is clear evidence that immunity can be induced 
experimentally with p67/SPAG1, a single infection event induces 
very little antibody specific for p67/SPAG1 and it is not clear 
whether such responses play a role in immunity in animals resid-
ing in endemic areas. Hence, this immunity could be described as 
“unnatural”. Second, there is marked skewing and dominance in the 
antigenic specificity of CD8 T- cell responses of individual animals, 
which is influenced by the MHC genotype of the animal, such that 
strain- specific immunity may be engendered by T- cell responses to 
one or two dominant epitopes in polymorphic antigens. Therefore, 
there is a need to re- examine the cross- protective potential of 
T. parva and T. annulata in cattle of MHC types known to respond 
to conserved epitopes. Great strides have been made in unravelling 
candidate Theileria vaccine antigens, and clear progress has been 
made in developing species- specific vaccines. The shared antigens 
raise the intriguing possibility of developing multivalent vaccines 
effective against the major pathogenic bovine and ovine species 
of Theileria.
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